JP2017534638A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017534638A5 JP2017534638A5 JP2017524049A JP2017524049A JP2017534638A5 JP 2017534638 A5 JP2017534638 A5 JP 2017534638A5 JP 2017524049 A JP2017524049 A JP 2017524049A JP 2017524049 A JP2017524049 A JP 2017524049A JP 2017534638 A5 JP2017534638 A5 JP 2017534638A5
- Authority
- JP
- Japan
- Prior art keywords
- weeks
- pharmaceutical composition
- mammal
- bcva
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000124008 Mammalia Species 0.000 claims description 37
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 28
- 238000000034 method Methods 0.000 claims description 25
- 201000006165 Kuhnt-Junius degeneration Diseases 0.000 claims description 23
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 23
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 23
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims description 23
- 239000005557 antagonist Substances 0.000 claims description 23
- 230000009266 disease activity Effects 0.000 claims description 20
- 208000031513 cyst Diseases 0.000 claims description 14
- 239000012530 fluid Substances 0.000 claims description 14
- 230000004304 visual acuity Effects 0.000 claims description 14
- 210000001525 retina Anatomy 0.000 claims description 12
- 206010011732 Cyst Diseases 0.000 claims description 10
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 238000011156 evaluation Methods 0.000 claims description 2
- 230000000007 visual effect Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 29
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462076770P | 2014-11-07 | 2014-11-07 | |
| US62/076,770 | 2014-11-07 | ||
| US201462088061P | 2014-12-05 | 2014-12-05 | |
| US62/088,061 | 2014-12-05 | ||
| PCT/US2015/059575 WO2016073918A1 (en) | 2014-11-07 | 2015-11-06 | Methods for treating ocular diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020138531A Division JP2020193212A (ja) | 2014-11-07 | 2020-08-19 | 眼疾患を処置する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017534638A JP2017534638A (ja) | 2017-11-24 |
| JP2017534638A5 true JP2017534638A5 (cg-RX-API-DMAC7.html) | 2018-12-06 |
| JP6753848B2 JP6753848B2 (ja) | 2020-09-09 |
Family
ID=54697654
Family Applications (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017523878A Active JP6667519B2 (ja) | 2014-11-07 | 2015-11-06 | 高濃度の抗ｖｅｇｆ抗体を含有する安定状態のタンパク質溶液製剤 |
| JP2017524049A Active JP6753848B2 (ja) | 2014-11-07 | 2015-11-06 | 眼疾患を処置する方法 |
| JP2020000823A Active JP7080263B2 (ja) | 2014-11-07 | 2020-01-07 | 高濃度の抗ｖｅｇｆ抗体を含有する安定状態のタンパク質溶液製剤 |
| JP2020138531A Withdrawn JP2020193212A (ja) | 2014-11-07 | 2020-08-19 | 眼疾患を処置する方法 |
| JP2022119423A Pending JP2022141923A (ja) | 2014-11-07 | 2022-07-27 | 眼疾患を処置する方法 |
| JP2024170733A Pending JP2025004075A (ja) | 2014-11-07 | 2024-09-30 | 眼疾患を処置する方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017523878A Active JP6667519B2 (ja) | 2014-11-07 | 2015-11-06 | 高濃度の抗ｖｅｇｆ抗体を含有する安定状態のタンパク質溶液製剤 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020000823A Active JP7080263B2 (ja) | 2014-11-07 | 2020-01-07 | 高濃度の抗ｖｅｇｆ抗体を含有する安定状態のタンパク質溶液製剤 |
| JP2020138531A Withdrawn JP2020193212A (ja) | 2014-11-07 | 2020-08-19 | 眼疾患を処置する方法 |
| JP2022119423A Pending JP2022141923A (ja) | 2014-11-07 | 2022-07-27 | 眼疾患を処置する方法 |
| JP2024170733A Pending JP2025004075A (ja) | 2014-11-07 | 2024-09-30 | 眼疾患を処置する方法 |
Country Status (24)
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2828739T3 (es) | 2006-04-07 | 2021-05-27 | Aerpio Pharmaceuticals Inc | Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y sus usos |
| US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| SI2752428T1 (sl) | 2008-06-25 | 2020-03-31 | Novartis Ag | Humaniziranje zajčjih protiteles z uporabo univerzalnega ogrodja protitelesa |
| AU2009264564B2 (en) | 2008-06-25 | 2014-05-08 | Novartis Ag | Stable and soluble antibodies inhibiting TNFalpha |
| US8569348B2 (en) | 2009-07-06 | 2013-10-29 | Aerpio Therapeutics Inc. | Compounds, compositions, and methods for preventing metastasis of cancer cells |
| EP3222285A1 (en) | 2011-01-13 | 2017-09-27 | Regeneron Pharmaceuticals, Inc. | Use of a vegf antagonist to treat angiogenic eye disorders |
| US20130095065A1 (en) | 2011-10-13 | 2013-04-18 | Aerpio Therapeutics, Inc. | Methods for Treating Vascular Leak Syndrome and Cancer |
| US20150050277A1 (en) | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
| EP3116503A4 (en) | 2014-03-14 | 2017-08-23 | Aerpio Therapeutics, Inc. | Hptp-beta inhibitors |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| TWI806150B (zh) | 2014-11-07 | 2023-06-21 | 瑞士商諾華公司 | 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物 |
| US10633433B2 (en) | 2015-01-28 | 2020-04-28 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| EP3250596A1 (en) | 2015-01-28 | 2017-12-06 | Pfizer Inc | Stable aqueous anti- vascular endothelial growth factor (vegf) antibody formulation |
| US9879080B2 (en) | 2015-01-28 | 2018-01-30 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| US10464999B2 (en) | 2015-01-28 | 2019-11-05 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| EP3977994B1 (en) | 2015-09-23 | 2024-04-24 | EyePoint Pharmaceuticals, Inc. | Activators of tie-2 for use in treating intraocular pressure |
| CN108699557B (zh) | 2015-12-04 | 2025-08-15 | 诺华股份有限公司 | 用于免疫肿瘤学的组合物和方法 |
| JP7088454B2 (ja) | 2015-12-30 | 2022-06-21 | コディアック サイエンシーズ インコーポレイテッド | 抗体および抗体複合体 |
| SG11201900464TA (en) | 2016-07-20 | 2019-02-27 | Aerpio Therapeutics Inc | HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß) |
| KR102124286B1 (ko) * | 2016-09-07 | 2020-06-18 | 삭신 라이프사이언스 피브이티 엘티디 | Vegf에 대한 합성 항체 및 이들의 용도 |
| US11692027B2 (en) | 2016-09-28 | 2023-07-04 | Board Of Regents, The University Of Texas System | Antibody and protein therapeutic formulations and uses thereof |
| EP3543337B1 (en) | 2016-11-18 | 2022-04-20 | Astellas Pharma Inc. | Novel anti-human muc1 antibody fab fragment |
| CN110832075A (zh) | 2017-03-22 | 2020-02-21 | 诺华股份有限公司 | 用于免疫肿瘤学的组合物和方法 |
| JOP20190245A1 (ar) | 2017-04-20 | 2019-10-15 | Novartis Ag | أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط |
| CN109562166B (zh) * | 2017-04-28 | 2021-04-02 | 苏州思坦维生物技术股份有限公司 | 一种眼用药物组合物及其用途 |
| TWI795415B (zh) | 2017-07-07 | 2023-03-11 | 日商安斯泰來製藥股份有限公司 | 新穎的抗人類ＣＥＡＣＡＭ５抗體Ｆａｂ片段 |
| WO2019020777A1 (en) * | 2017-07-26 | 2019-01-31 | Formycon Ag | LIQUID FORMULATION OF A VEGF ANTAGONIST |
| MX2020003041A (es) | 2017-10-06 | 2020-10-05 | Prothena Biosciences Ltd | Anticuerpos anti-transtiretina. |
| CN111757730A (zh) | 2017-10-06 | 2020-10-09 | 普罗塞纳生物科学有限公司 | 检测甲状腺素运载蛋白的方法 |
| AU2018375356A1 (en) * | 2017-11-29 | 2020-05-14 | Neotope Neuroscience Limited | Lyophilized formulation of a monoclonal antibody against transthyretin |
| CN111465407A (zh) | 2017-11-30 | 2020-07-28 | 瑞泽恩制药公司 | 使用vegf拮抗剂治疗生血管性眼病 |
| CN111699004A (zh) * | 2018-02-06 | 2020-09-22 | 豪夫迈·罗氏有限公司 | 眼科疾病的治疗 |
| CN112203679A (zh) | 2018-03-02 | 2021-01-08 | 科达制药股份有限公司 | Il-6抗体及其融合构建体和缀合物 |
| JP6938796B2 (ja) * | 2018-03-16 | 2021-09-22 | ノバルティス アーゲー | 眼疾患を治療するための方法 |
| EP3768706A1 (en) * | 2018-03-23 | 2021-01-27 | AbbVie Deutschland GmbH & Co. KG | Stable aqueous anti-tau antibody formulations |
| EP3775267A4 (en) * | 2018-04-10 | 2022-05-18 | Askgene Pharma, Inc. | NOVEL ANGIOPOIETIN-2, VEGF DUAL ANTAGONISTS |
| JP7235770B2 (ja) | 2018-05-10 | 2023-03-08 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 高濃度ｖｅｇｆ受容体融合タンパク質を含む製剤 |
| JP7360766B2 (ja) | 2018-05-17 | 2023-10-13 | アステラス製薬株式会社 | 抗ヒトＭＵＣ１抗体Ｆａｂフラグメント、ペプチドリンカー及び／又は配位子を含む複合体 |
| EP3856245A4 (en) * | 2018-09-24 | 2022-10-26 | EyePoint Pharmaceuticals, Inc. | MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - ß (VE-PTP) AND VEGF |
| AR116566A1 (es) | 2018-10-03 | 2021-05-19 | Novartis Ag | Administración sostenida de polipéptidos similares a la angiopoyetina 3 |
| JP7374544B2 (ja) * | 2018-10-10 | 2023-11-07 | アステラス製薬株式会社 | 標識部－抗ヒト抗体Ｆａｂフラグメント複合体を含む医薬組成物 |
| WO2020089051A1 (en) * | 2018-10-29 | 2020-05-07 | F. Hoffmann-La Roche Ag | Antibody formulation |
| CA3119179A1 (en) | 2018-11-07 | 2020-05-14 | Applied Molecular Transport Inc. | Cholix-derived carriers for oral delivery of heterologous payload |
| US11945859B2 (en) * | 2018-12-18 | 2024-04-02 | Novartis Ag | Protein solution formulation containing high concentration of an anti-VEGF antibody |
| MA55033A (fr) | 2019-02-18 | 2021-12-29 | Lilly Co Eli | Formulation d'anticorps thérapeutique |
| TWI862583B (zh) | 2019-04-26 | 2024-11-21 | 美商愛德維仁生物科技公司 | 用於玻璃體內遞送之變異體aav蛋白殼 |
| EP3962482A4 (en) | 2019-04-29 | 2023-01-11 | EyePoint Pharmaceuticals, Inc. | TIE 2 ACTIVATORS FACING THE SCHLEMM CHANNEL |
| JP2022544624A (ja) | 2019-08-16 | 2022-10-19 | アプライド モレキュラー トランスポート インコーポレイテッド | 組成物、製剤およびインターロイキンの生成および精製 |
| WO2021072265A1 (en) * | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| CN111217834B (zh) * | 2020-02-21 | 2021-10-26 | 维眸生物科技（上海）有限公司 | Rock激酶抑制剂的硝基氧衍生物 |
| EP4115903A4 (en) * | 2020-03-04 | 2023-12-20 | Shanghai Henlius Biotech, Inc. | Pharmaceutical formulation comprising bevacizumab |
| WO2021233408A1 (zh) * | 2020-05-21 | 2021-11-25 | 迈威(上海)生物科技股份有限公司 | 抗α-溶血素的抗体及其稳定制剂 |
| KR20220001106A (ko) | 2020-06-29 | 2022-01-05 | (주)메디톡스 | 고농도 항-ｖｅｇｆ 항체 제제 및 이에 사용하기 위한 항-ｖｅｇｆ 항체 |
| MX2023000547A (es) | 2020-07-16 | 2023-02-13 | Novartis Ag | Anticuerpos anti-betacelulina, fragmentos de los mismos, y moleculas de union multiespecificas. |
| IL308505A (en) * | 2021-05-17 | 2024-01-01 | Regeneron Pharma | Continuous high-dose VEGF antagonist regimens for the treatment of angiogenic ocular disorders |
| CN113940997B (zh) * | 2021-12-21 | 2022-04-08 | 迈威(上海)生物科技股份有限公司 | 一种双特异性抗体的稳定制剂 |
| EP4588469A1 (en) * | 2022-09-16 | 2025-07-23 | Qilu Pharmaceutical Co., Ltd. | Stable high-concentration self-buffering pharmaceutical composition |
| WO2025231345A1 (en) * | 2024-05-03 | 2025-11-06 | Therini Bio, Inc. | Doses of antibodies which bind human fibrin yc or fibrinogen yc domain for ocular diseases |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| JO3000B1 (ar) * | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| PL1802334T3 (pl) | 2004-10-21 | 2013-01-31 | Genentech Inc | Sposób leczenia wewnątrzgałkowych chorób neowaskularnych |
| WO2007011873A2 (en) * | 2005-07-15 | 2007-01-25 | Genentech, Inc. | Method for treating intraocular neovascular diseases |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| RU2432155C3 (ru) * | 2006-06-16 | 2017-11-17 | Ридженерон Фармасьютикалз, Инк. | Составы антагониста vegf, подходящие для интравитреального введения |
| US20090175847A1 (en) | 2007-05-30 | 2009-07-09 | Abbott Laboratories | Humanized antibodies to ab (20-42) globulomer and uses thereof |
| AR069501A1 (es) | 2007-11-30 | 2010-01-27 | Genentech Inc | Anticuerpos anti- vegf (factor de crecimiento endotelial vascular) |
| PE20091174A1 (es) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
| LT3216803T (lt) * | 2008-06-25 | 2020-06-10 | Novartis Ag | Stabilūs ir tirpūs antikūnai, slopinantys vegf |
| AU2009264564B2 (en) | 2008-06-25 | 2014-05-08 | Novartis Ag | Stable and soluble antibodies inhibiting TNFalpha |
| SI2752428T1 (sl) | 2008-06-25 | 2020-03-31 | Novartis Ag | Humaniziranje zajčjih protiteles z uporabo univerzalnega ogrodja protitelesa |
| KR101678925B1 (ko) | 2008-06-30 | 2016-11-24 | 에스바테크 - 어 노바티스 컴파니 엘엘씨 | 기능화 폴리펩티드 |
| SG181834A1 (en) | 2009-12-21 | 2012-07-30 | Genentech Inc | Antibody formulation |
| EP2648750B1 (en) | 2010-12-10 | 2017-01-25 | Novartis AG | Antibody formulation |
| EP3222285A1 (en) * | 2011-01-13 | 2017-09-27 | Regeneron Pharmaceuticals, Inc. | Use of a vegf antagonist to treat angiogenic eye disorders |
| WO2013003680A1 (en) * | 2011-06-30 | 2013-01-03 | Genentech, Inc. | Anti-c-met antibody formulations |
| CN109608543A (zh) * | 2011-10-20 | 2019-04-12 | 艾斯巴技术-诺华有限责任公司 | 稳定的多抗原结合抗体 |
| HK1208382A1 (en) | 2012-05-03 | 2016-03-04 | 卡拉制药公司 | Pharmaceutical nanoparticles showing improved mucosal transport |
| US20140004131A1 (en) | 2012-05-04 | 2014-01-02 | Novartis Ag | Antibody formulation |
| US9216219B2 (en) | 2012-06-12 | 2015-12-22 | Novartis Ag | Anti-BAFFR antibody formulation |
| JOP20200175A1 (ar) | 2012-07-03 | 2017-06-16 | Novartis Ag | حقنة |
| UA117466C2 (uk) * | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
| SG11201507475UA (en) | 2013-03-13 | 2015-10-29 | Genentech Inc | Antibody formulations |
| WO2015086830A1 (en) * | 2013-12-13 | 2015-06-18 | Delenex Therapeutics Ag | Skin penetrating polypeptides |
| US9388239B2 (en) | 2014-05-01 | 2016-07-12 | Consejo Nacional De Investigation Cientifica | Anti-human VEGF antibodies with unusually strong binding affinity to human VEGF-A and cross reactivity to human VEGF-B |
| MX2016016836A (es) * | 2014-06-17 | 2017-07-27 | Clearside Biomedical Inc | Metodos y dispositivos para tratar trastornos oculares posteriores. |
| TWI806150B (zh) | 2014-11-07 | 2023-06-21 | 瑞士商諾華公司 | 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物 |
| US20160144025A1 (en) | 2014-11-25 | 2016-05-26 | Regeneron Pharmaceuticals, Inc. | Methods and formulations for treating vascular eye diseases |
| JP6938796B2 (ja) | 2018-03-16 | 2021-09-22 | ノバルティス アーゲー | 眼疾患を治療するための方法 |
| US11945859B2 (en) | 2018-12-18 | 2024-04-02 | Novartis Ag | Protein solution formulation containing high concentration of an anti-VEGF antibody |
-
2015
- 2015-10-26 TW TW110133255A patent/TWI806150B/zh active
- 2015-10-26 TW TW109132401A patent/TWI761959B/zh active
- 2015-10-26 TW TW104135105A patent/TWI738632B/zh active
- 2015-10-26 TW TW104135104A patent/TWI705827B/zh active
- 2015-11-06 KR KR1020237014727A patent/KR102724014B1/ko active Active
- 2015-11-06 SG SG11201702954XA patent/SG11201702954XA/en unknown
- 2015-11-06 KR KR1020177014978A patent/KR102588846B1/ko active Active
- 2015-11-06 SG SG10201913565RA patent/SG10201913565RA/en unknown
- 2015-11-06 KR KR1020177012256A patent/KR20170082526A/ko not_active Ceased
- 2015-11-06 SG SG11201702909QA patent/SG11201702909QA/en unknown
- 2015-11-06 WO PCT/US2015/059575 patent/WO2016073918A1/en not_active Ceased
- 2015-11-06 KR KR1020247035792A patent/KR20240161204A/ko not_active Ceased
- 2015-11-06 US US14/934,731 patent/US10035850B2/en active Active
- 2015-11-06 BR BR112017008093-1A patent/BR112017008093A2/pt not_active Application Discontinuation
- 2015-11-06 AU AU2015342815A patent/AU2015342815B2/en active Active
- 2015-11-06 MX MX2017005875A patent/MX383399B/es unknown
- 2015-11-06 US US14/934,666 patent/US10689438B2/en active Active
- 2015-11-06 AU AU2015342818A patent/AU2015342818B2/en active Active
- 2015-11-06 PH PH1/2021/550147A patent/PH12021550147A1/en unknown
- 2015-11-06 MX MX2017005874A patent/MX383808B/es unknown
- 2015-11-06 WO PCT/US2015/059571 patent/WO2016073915A1/en not_active Ceased
- 2015-11-06 BR BR112017008660A patent/BR112017008660A2/pt not_active Application Discontinuation
- 2015-11-06 CN CN201580060416.5A patent/CN107635580A/zh active Pending
- 2015-11-06 EP EP15798609.2A patent/EP3215122B1/en active Active
- 2015-11-06 RU RU2017119647A patent/RU2722643C2/ru active
- 2015-11-06 PE PE2017000812A patent/PE20170780A1/es unknown
- 2015-11-06 NZ NZ73082115A patent/NZ730821A/en unknown
- 2015-11-06 JP JP2017523878A patent/JP6667519B2/ja active Active
- 2015-11-06 TN TN2017000128A patent/TN2017000128A1/en unknown
- 2015-11-06 EP EP15807721.4A patent/EP3215123A1/en active Pending
- 2015-11-06 CN CN202511153148.3A patent/CN120938921A/zh active Pending
- 2015-11-06 EA EA201790989A patent/EA201790989A1/ru unknown
- 2015-11-06 MY MYPI2020002268A patent/MY193913A/en unknown
- 2015-11-06 CN CN201580060665.4A patent/CN106999581A/zh active Pending
- 2015-11-06 MY MYPI2017701217A patent/MY183807A/en unknown
- 2015-11-06 CA CA2966646A patent/CA2966646A1/en active Pending
- 2015-11-06 CN CN202111376360.8A patent/CN114081951A/zh active Pending
- 2015-11-06 JP JP2017524049A patent/JP6753848B2/ja active Active
-
2017
- 2017-04-06 IL IL251642A patent/IL251642B/en active IP Right Grant
- 2017-04-12 IL IL251696A patent/IL251696A0/en active IP Right Grant
- 2017-05-04 MX MX2021006768A patent/MX2021006768A/es unknown
- 2017-05-05 PH PH12017500844A patent/PH12017500844B1/en unknown
- 2017-05-05 CO CONC2017/0004596A patent/CO2017004596A2/es unknown
- 2017-05-05 CL CL2017001115A patent/CL2017001115A1/es unknown
- 2017-05-05 PH PH12017500843A patent/PH12017500843A1/en unknown
- 2017-05-05 GT GT201700096A patent/GT201700096A/es unknown
- 2017-05-05 CL CL2017001117A patent/CL2017001117A1/es unknown
- 2017-06-05 EC ECIEPI201734829A patent/ECSP17034829A/es unknown
-
2018
- 2018-06-26 US US16/018,244 patent/US11098110B2/en active Active
- 2018-12-04 AU AU2018274882A patent/AU2018274882B2/en active Active
- 2018-12-11 AU AU2018278870A patent/AU2018278870B2/en active Active
-
2019
- 2019-03-20 IL IL265497A patent/IL265497B/en active IP Right Grant
-
2020
- 2020-01-07 JP JP2020000823A patent/JP7080263B2/ja active Active
- 2020-05-11 US US16/871,765 patent/US12049495B2/en active Active
- 2020-08-19 JP JP2020138531A patent/JP2020193212A/ja not_active Withdrawn
- 2020-08-21 AU AU2020220210A patent/AU2020220210B2/en active Active
- 2020-10-05 AU AU2020244614A patent/AU2020244614B2/en active Active
-
2021
- 2021-01-11 IL IL280087A patent/IL280087B/en unknown
- 2021-05-30 IL IL283561A patent/IL283561B/en unknown
- 2021-07-16 US US17/378,618 patent/US12371481B2/en active Active
-
2022
- 2022-07-27 JP JP2022119423A patent/JP2022141923A/ja active Pending
-
2024
- 2024-09-30 JP JP2024170733A patent/JP2025004075A/ja active Pending